Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.

[1]  M. Hüfner,et al.  Cytokines, Osteoprotegerin, and RANKL In Vitro and Histomorphometric Indices of Bone Turnover in Patients With Different Bone Diseases , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  B. Halloran,et al.  Expression of RANKL and OPG Correlates With Age‐Related Bone Loss in Male C57BL/6 Mice , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  N. Athanasou,et al.  Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. , 2002, Bone.

[4]  P. Tak,et al.  Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis , 2002, Annals of the rheumatic diseases.

[5]  S. Beaudin,et al.  Neutralization of interleukin-11 activity decreases osteoclast formation and increases cancellous bone volume in ovariectomized mice. , 2002, Cytokine.

[6]  R. Kitazawa,et al.  Transforming Growth Factor- (cid:1) Induces Expression of Receptor Activator of NF- (cid:2) B Ligand in Vascular Endothelial Cells Derived from Bone* , 2002 .

[7]  U. Lerner,et al.  Characterization of the bone-resorptive effect of interleukin-11 in cultured mouse calvarial bones. , 2002, Bone.

[8]  Sandrine Bongiovanni,et al.  Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB* , 2002, The Journal of Biological Chemistry.

[9]  J. Pfeilschifter,et al.  Changes in proinflammatory cytokine activity after menopause. , 2002, Endocrine reviews.

[10]  D. Howie,et al.  The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. , 2001, The Journal of bone and joint surgery. British volume.

[11]  N. Fazzalari,et al.  The Ratio of Messenger RNA Levels of Receptor Activator of Nuclear Factor κB Ligand to Osteoprotegerin Correlates with Bone Remodeling Indices in Normal Human Cancellous Bone but Not in Osteoarthritis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  L. Hofbauer,et al.  Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.

[13]  M. Seibel,et al.  Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. , 2001, The Journal of clinical endocrinology and metabolism.

[14]  F. Ross,et al.  Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK Activation* , 2001, The Journal of Biological Chemistry.

[15]  T. Björkman,et al.  Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. , 2001, Biochemical and biophysical research communications.

[16]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[17]  R. Lorentzon,et al.  Interleukin‐6 Gene Polymorphism Is Related to Bone Mineral Density During and After Puberty in Healthy White Males: A Cross‐Sectional and Longitudinal Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  S. Yamasaki,et al.  Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. , 2000, Biochemical and biophysical research communications.

[19]  A. Evdokiou,et al.  Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell Tumors , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  O. Johnell,et al.  Prediction of fracture from low bone mineral density measurements overestimates risk. , 2000, Bone.

[21]  H. Schunkert,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Hormone Replacement Therapy and Interrelation between Serum Interleukin-6 and Body Mass Index in Postmenopausal Women: A Population-Based Study , 2022 .

[22]  N. Fazzalari,et al.  Enhanced Expression of Osteocalcin mRNA in Human Osteoarthritic Trabecular Bone of the Proximal Femur Is Associated with Decreased Expression of Interleukin‐6 and Interleukin‐11 mRNA , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  D. E. Faunce,et al.  Immunosuppression , 2001, Acta Chirurgica Austriaca.

[24]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[26]  R. Pacifici.  Aging and Cytokine Production , 1999, Calcified Tissue International.

[27]  J. Hopper,et al.  Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. , 1999, The Journal of clinical endocrinology and metabolism.

[28]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[29]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[30]  C. O’Brien,et al.  STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.

[31]  N. Udagawa,et al.  A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. , 1999, Biochemical and biophysical research communications.

[32]  T. Martin,et al.  Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. , 1998, Endocrinology.

[33]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[34]  B. Riggs,et al.  Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. , 1998, Biochemical and biophysical research communications.

[35]  Li Sun,et al.  Mode of Action of Interleukin-6 on Mature Osteoclasts. Novel Interactions with Extracellular Ca2+ Sensing in the Regulation of Osteoclastic Bone Resorption , 1998, The Journal of cell biology.

[36]  S. Miller,et al.  Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. , 1998, Bone.

[37]  R. Jilka,et al.  Cytokines, bone remodeling, and estrogen deficiency: a 1998 update. , 1998, Bone.

[38]  K. Sjögren,et al.  Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. , 1998, Biochemical and biophysical research communications.

[39]  K Yano,et al.  Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.

[40]  C. Ohlsson,et al.  Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. , 1998, Biochemical and biophysical research communications.

[41]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[43]  T. Martin,et al.  Hormonal Regulation of Osteoclast Function , 1998, Trends in Endocrinology & Metabolism.

[44]  E. Jimi,et al.  Regulation of Osteoclast Function , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[45]  J. Puzas,et al.  Osteoclasts constitutively express regulators of bone resorption: an immunohistochemical and in situ hybridization study. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[46]  A. Grey,et al.  Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[47]  P. Ross.  Osteoporosis. Frequency, consequences, and risk factors. , 1996, Archives of internal medicine.

[48]  T. Martin,et al.  The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures , 1996, The Journal of experimental medicine.

[49]  N. Udagawa,et al.  Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  R. Ziegler,et al.  Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. , 1995, The Journal of clinical endocrinology and metabolism.

[51]  S. Akira,et al.  Interleukin-6 family of cytokines and gp130. , 1995, Blood.

[52]  G. Roodman.  Osteoclast function in Paget's disease and multiple myeloma. , 1995, Bone.

[53]  L. Selvaggi,et al.  Effect of oestrogen replacement on bone metabolism and cytokines in surgical menopause , 1995, Clinical Rheumatology.

[54]  R. Jilka,et al.  New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130. , 1995, International journal of immunopharmacology.

[55]  M. Lacroix,et al.  Regulation of lymphocyte calcitonin receptors by interleukin-1 and interleukin-6 , 1994, Calcified Tissue International.

[56]  G. Passeri,et al.  Increased interleukin-6 production by murine bone marrow and bone cells after estrogen withdrawal. , 1993, Endocrinology.

[57]  C. Cooper,et al.  Hip fractures in the elderly: A world-wide projection , 1992, Osteoporosis International.

[58]  H. Broxmeyer,et al.  Increased osteoclast development after estrogen loss: mediation by interleukin-6 , 1992 .

[59]  G. Roodman.  Perspectives: Interleukin‐6: An osteotropic factor? , 1992 .

[60]  G. Passeri,et al.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. , 1992, The Journal of clinical investigation.

[61]  T. Linkhart,et al.  Interleukin‐6 messenger RNA expression and interleukin‐6 protein secretion in cells isolated from normal human bone: Regulation by interleukin‐1 , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[62]  E. Puscheck,et al.  Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[63]  S. Ralston,et al.  Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[64]  T. Suda,et al.  IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. , 1990, Journal of immunology.

[65]  L. Aarden,et al.  Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. , 1989, Biochemical and biophysical research communications.

[66]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[67]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[68]  B. Vernon‐roberts,et al.  Absence of metabolic bone disease in the proximal femur in patients with fracture of the femoral neck. , 1982, The Journal of bone and joint surgery. British volume.

[69]  C. Neer,et al.  Recent experience in total shoulder replacement. , 1982, The Journal of bone and joint surgery. American volume.

[70]  N Loveridge,et al.  Regional differences in cortical porosity in the fractured femoral neck. , 1999, Bone.

[71]  G D Roodman,et al.  Interleukin 6. A potential autocrine/paracrine factor in Paget's disease of bone. , 1992, The Journal of clinical investigation.

[72]  B. Vernon‐roberts,et al.  Histomorphometric changes in the trabecular structure of a selected stress region in the femur in patients with osteoarthritis and fracture of the femoral neck. , 1985, Bone.